3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Hodgkin Disease
1
Interventions
Cyclophosphamide
38
fludarabine
30
Rituximab
26
obinutuzumab
10
Bendamustine Hydrochloride
10
fludarabine phosphate
9
pembrolizumab
8
Specimen Handling
7
Etoposide
7
venetoclax
6
Vincristine
6
Prednisone
6
Magnetic Resonance Spectroscopy
6
Leukapheresis
6
Lenalidomide
6
ibrutinib
5
Inotuzumab Ozogamicin
5
Immunotherapy, Adoptive
5
Doxorubicin
5
Biopsy
5
ublituximab
4
tazemetostat
4
glofitamab
4
Interleukin-2
4
Dexamethasone
4
Cytarabine
4
pomalidomide
3
polatuzumab vedotin
3
Radiation
3
Nivolumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Lymphoma, B-Cell
×
tenalisib
×
Clear all
NCT02017613
2016-06-24
PI3K
Rhizen Pharmaceuticals SA
Phase 1
Completed
35 enrolled